Company intelligence / Profile preview
Minerva Neurosciences, Inc.
Cambridge*, Massachusetts, United Statesminervaneurosciences.com ↗
- Ownership
- Public · NERV
- Employees
- ~45
- Development stage
- Other
01
Overview
Minerva Neurosciences’ lead candidate roluperidone has completed Phase 3 trials for the treatment of negative symptoms in schizophrenia. The company has demonstrated bioequivalence between its clinical and planned commercial formulations and has submitted a New Drug Application (NDA) to the FDA. No pharmacological agent is currently approved for this indication, representing a significant unmet need. Other pipeline programs are at earlier stages or have been deprioritized.
- Therapeutic areas
- PsychiatryNeurology
- Modalities
- small molecules
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
Janssen Pharmaceutical Companies of Johnson & Johnson—co-development/licensing agreement for seltorexant/MIN‑202 in certain territoriesBoehringer Ingelheim—private placement financing partner for roluperidone development
04
Financials
- Market cap
- $109.8M
- Total revenue
- $0
- Enterprise value
- $34.6M
Beyond the preview
Go deeper on Minerva Neurosciences, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Minerva Neurosciences, Inc..